345 related articles for article (PubMed ID: 32893683)
1. The pharmacotherapeutic management of gastroesophageal reflux disease (GERD).
Chapelle N; Ben Ghezala I; Barkun A; Bardou M
Expert Opin Pharmacother; 2021 Feb; 22(2):219-227. PubMed ID: 32893683
[TBL] [Abstract][Full Text] [Related]
2. More severe upper gastrointestinal symptoms associated with non-erosive reflux disease than with erosive gastroesophageal reflux disease during maintenance proton pump inhibitor therapy.
Kusano M; Hosaka H; Kawamura O; Kawada A; Kuribayashi S; Shimoyama Y; Yasuoka H; Mizuide M; Tomizawa T; Sagawa T; Sato K; Yamada M
J Gastroenterol; 2015 Mar; 50(3):298-304. PubMed ID: 24919745
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of Vonoprazan, a Novel Potassium-Competitive Acid Blocker, in Patients with Proton Pump Inhibitor-Refractory Acid Reflux.
Akiyama J; Hosaka H; Kuribayashi S; Moriyasu S; Hisada Y; Okubo H; Watanabe K; Imbe K; Nagata N; Kojima Y; Yokoi C; Uemura N; Shimoyama Y; Kawamura O; Yamada M; Kusano M
Digestion; 2020; 101(2):174-183. PubMed ID: 30897577
[TBL] [Abstract][Full Text] [Related]
4. A systematic review and meta-analysis of the efficacy of vonoprazan for proton pump inhibitor-resistant gastroesophageal reflux disease.
Simadibrata DM; Lesmana E; Fass R
J Gastroenterol Hepatol; 2024 May; 39(5):796-805. PubMed ID: 38263507
[TBL] [Abstract][Full Text] [Related]
5. Vonoprazan versus proton-pump inhibitors for healing gastroesophageal reflux disease: A systematic review.
Miyazaki H; Igarashi A; Takeuchi T; Teng L; Uda A; Deguchi H; Higuchi K; Tango T
J Gastroenterol Hepatol; 2019 Aug; 34(8):1316-1328. PubMed ID: 30883868
[TBL] [Abstract][Full Text] [Related]
6. Proton pump inhibitors in the management of gastroesophageal reflux disease.
Hrelja N; Zerem E
Med Arh; 2011; 65(1):52-5. PubMed ID: 21534455
[TBL] [Abstract][Full Text] [Related]
7. Investigation of pretreatment prediction of proton pump inhibitor (PPI)-resistant patients with gastroesophageal reflux disease and the dose escalation challenge of PPIs-TORNADO study: a multicenter prospective study by the Acid-Related Symptom Research Group in Japan.
Furuta T; Shimatani T; Sugimoto M; Ishihara S; Fujiwara Y; Kusano M; Koike T; Hongo M; Chiba T; Kinoshita Y;
J Gastroenterol; 2011 Nov; 46(11):1273-83. PubMed ID: 21861141
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of vonoprazan for initial and maintenance therapy in reflux esophagitis, nonerosive esophagitis, and proton pump inhibitor-resistant gastroesophageal reflux disease.
Gotoh Y; Ishibashi E; Honda S; Nakaya T; Noguchi C; Kagawa K; Murakami K
Medicine (Baltimore); 2020 Mar; 99(11):e19520. PubMed ID: 32176102
[TBL] [Abstract][Full Text] [Related]
9. Algorithmic approach to patients presenting with heartburn and epigastric pain refractory to empiric proton pump inhibitor therapy.
Roorda AK; Marcus SN; Triadafilopoulos G
Dig Dis Sci; 2011 Oct; 56(10):2871-8. PubMed ID: 21512760
[TBL] [Abstract][Full Text] [Related]
10. Updates in the Management of Erosive Esophagitis.
Pandolfino JE; Spechler SJ; Yadlapati R
J Fam Pract; 2023 Oct; 72(8 Suppl):S1-S12. PubMed ID: 37862630
[TBL] [Abstract][Full Text] [Related]
11. Characteristics of refractory gastroesophageal reflux disease (GERD) symptoms -is switching proton pump inhibitors based on the patient's CYP2C19 genotype an effective management strategy?
Takeuchi T; Oota K; Harada S; Edogawa S; Kojima Y; Sanomura M; Sakaguchi M; Hayashi K; Hongoh Y; Itabashi T; Kitae H; Hoshimoto M; Takeuchi N; Higuchi K
Intern Med; 2015; 54(2):97-105. PubMed ID: 25742999
[TBL] [Abstract][Full Text] [Related]
12. An update on the latest chemical therapies for reflux esophagitis in children.
Bardou M; Fortinsky KJ; Chapelle N; Luu M; Barkun A
Expert Opin Pharmacother; 2019 Feb; 20(2):231-239. PubMed ID: 30496693
[TBL] [Abstract][Full Text] [Related]
13. Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2021.
Iwakiri K; Fujiwara Y; Manabe N; Ihara E; Kuribayashi S; Akiyama J; Kondo T; Yamashita H; Ishimura N; Kitasako Y; Iijima K; Koike T; Omura N; Nomura T; Kawamura O; Ohara S; Ozawa S; Kinoshita Y; Mochida S; Enomoto N; Shimosegawa T; Koike K
J Gastroenterol; 2022 Apr; 57(4):267-285. PubMed ID: 35226174
[TBL] [Abstract][Full Text] [Related]
14. The Prevalence and Clinical Features of Non-responsive Gastroesophageal Reflux Disease to Practical Proton Pump Inhibitor Dose in Korea: A Multicenter Study.
Park HJ; Park SH; Shim KN; Kim YS; Kim HJ; Han JP; Kim YS; Bang BW; Kim GH; Baik GH; Kim HH; Park SY; Kim SS
Korean J Gastroenterol; 2016 Jul; 68(1):16-22. PubMed ID: 27443619
[TBL] [Abstract][Full Text] [Related]
15. Potassium-competitive acid blockers and gastroesophageal reflux disease.
Leowattana W; Leowattana T
World J Gastroenterol; 2022 Jul; 28(28):3608-3619. PubMed ID: 36161043
[TBL] [Abstract][Full Text] [Related]
16. Proton Pump Inhibitors in Gastroesophageal Reflux Disease: Friend or Foe.
Gyawali CP
Curr Gastroenterol Rep; 2017 Sep; 19(9):46. PubMed ID: 28780717
[TBL] [Abstract][Full Text] [Related]
17. Long-term outcomes of patients with symptomatic gastroesophageal reflux disease treated with vonoprazan.
Shinozaki S; Osawa H; Kobayashi Y; Sakamoto H; Hayashi Y; Miura Y; Kawarai Lefor A; Yamamoto H
Scand J Gastroenterol; 2018 Aug; 53(8):897-904. PubMed ID: 30056768
[TBL] [Abstract][Full Text] [Related]
18. Review of the clinical development of fexuprazan for gastroesophageal reflux-related disease.
Ramani A; Merchant A; Cash BD
Eur J Clin Pharmacol; 2023 Aug; 79(8):1023-1029. PubMed ID: 37344679
[TBL] [Abstract][Full Text] [Related]
19. Proton Pump Inhibitor Treatment Has Little Effects on Secretion of Saliva in Patients with Proton Pump Inhibitor-Responsive Mild Reflux Esophagitis and Non-Erosive Reflux Disease.
Hoshikawa Y; Momma E; Hoshino S; Kawami N; Kitasako Y; Ikeda M; Iwakiri K
Digestion; 2023; 104(3):187-192. PubMed ID: 36580899
[TBL] [Abstract][Full Text] [Related]
20. Symptoms and quality of life in underweight gastroesophageal reflux disease patients and therapeutic responses to proton pump inhibitors.
Hongo M; Miwa H; Kusano M;
J Gastroenterol Hepatol; 2012 May; 27(5):913-8. PubMed ID: 22142515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
